Syndax appoints Neil Gallagher as President, Head of R&D; Morrison transitions

Syndax Pharmaceuticals Inc

Neil Gallagher, M.D., Ph.D., appointed President, Head of R&D effective April 10, 2023; previously CMO at AbbVie.
Briggs Morrison resigns as President, Head of R&D effective April 15, 2023; will consult for 3 months, remains on board.
Gallagher receives $530k base salary, 45% target bonus, and inducement option for 250k shares vesting over 4 years.
Company expects to advance revumenib and axatilimab through pivotal data and regulatory filings in 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Briggs W. Morrison

President, Head of Research and Development

SNDX · Syndax Pharmaceuticals Inc

Effective: 2023-04-15
Successor: Neil Gallagher
Filed: March 30, 2023, 7:59 PM ET

On March 29, 2023, Briggs W. Morrison M.D., President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.

Appointed

Neil Gallagher

President, Head of Research and Development

SNDX · Syndax Pharmaceuticals Inc

Effective: 2023-04-10
Filed: March 30, 2023, 7:59 PM ET

On March 30, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Neil Gallagher, M.D., Ph.D., will join the Company as President, Head of Research and Development, effective April 10, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Briggs W. Morrison resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

Action: resigned
Role: President, Head of Research and Development

Exact text from the filing

On March 29, 2023, Briggs W. Morrison M.D., President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Gallagher was appointed as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

Action: appointed
Role: President, Head of Research and Development

Exact text from the filing

On March 30, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Neil Gallagher, M.D., Ph.D., will join the Company as President, Head of Research and Development, effective April 10, 2023.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-010756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.